MWR

MORBIDITY AND MORTALITY WEEKLY REPORT

- 69 Viral Gastroenteritis South Dakota and New Mexico
- 72 Recommendations for Protecting Human Health Against Potential Adverse Effects of Long-Term Exposure to Low Doses of Chemical Warfare Agents
- 79 La Crosse Encephalitis in West Virginia
- 82 Influenza Update United States

Epidemiologic Notes and Reports

Viral Gastroenteritis - South Dakota and New Mexico

The following reports describe two outbreaks of viral gastroenteritis associated with contaminated water.

South Dakota. An outbreak of diarrhea occurred among the 331 participants in an outing held at a South Dakota campground on August 30 and 31, 1986. During the event, in which participants hiked 10 or 20 km, water and a reconstituted soft drink were available at rest stands. The State Department of Health conducted a survey of 181 participants: 135 (75%) of these persons reported a gastrointestinal illness. Symptoms most frequently reported were diarrhea (69%), explosive vomiting (55%), nausea (49%), headache (47%), abdominal cramping (46%), and fever (36%). None of the participants required hospitalization. Attack rates by sex and age of patients were virtually equal. Onset of illness occurred 35 hours (mean) after arrival at the campground, and duration of illness was about 33 hours.

A biotin-avidin immunoassay performed at CDC yielded a fourfold rise in antibody titer to Norwalk virus in seven of 11 paired human serum specimens. No pathogenic bacterial or parasitic agents were identified from stool samples. Illness was strongly associated with the consumption of water or the reconstituted powdered soft drink made with water. No other foodstuffs were implicated. The implicated water came from a well at the campground. A yard hydrant was located next to a septic dump station, where sewage from self-contained septic tanks and portable toilets in the park was collected. Water from this hydrant had been used to fill water coolers and to prepare the powdered soft drink. Laboratory analyses of remaining water and reconstituted soft drink samples showed bacterial contamination (fecal coliforms >1,600 cfu/100 mL). Chlorine was stored in a tank and then drawn directly into the water system by a pump without a monitoring system. Water samples obtained from various locations in the campground had excess coliforms when the chlorination

Viral Gastroenteritis - Continued

system was not operating. Fluorescent dye injected into a 5,000-gallon septic tank situated uphill from the well confirmed that the well was contaminated with sewage.

This campground was closed immediately and voluntarily by the owner. Corrective measures included relocating the well, installing an alarm system to detect malfunctions in the chlorination system, reconstructing the chlorination system to ensure that chlorine remains in contact with water in a storage tank for 30 minutes before the water is distributed, maintaining a daily log on chlorine residuals and sample collection points, and posting the yard hydrant as a nonpotable source of water.

New Mexico. An outbreak of gastroenteritis occurred among the 92 guests and staff at a cabin lodge in northern New Mexico over the Labor Day weekend in 1986. The guests arrived Friday, August 29, and provided their own food for the weekend. The first persons to become ill developed diarrhea on Saturday morning, within 24 hours after arrival. By Wednesday, 36 of the guests and staff members reported symptoms: 34 had diarrhea; 9, vomiting; 14, fever; 22, abdominal cramps; and 1, bloody stools. There were no deaths or hospitalizations.

A questionnaire was administered to all 92 guests and staff to ascertain risk factors for gastroenteritis. Guests consisted of unrelated groups, and they stayed in 18 separate cabins. All 36 of the patients and 37 of the 56 unaffected attendees had drunk water at their cabin. A dose-response relationship was demonstrated between the amount of water consumed and the attack rate. No illness occurred among the persons who did not drink water; 33% of those drinking 1-2 cups and 59% of those drinking \geqslant 3 cups became ill. Five of the 18 cabins were unaffected; three of these belonged to families who were residents or frequent visitors at the lodge.

Assuming guests were exposed upon arrival or when they first drank water, the median incubation period was 41 hours (range = 7-110 hours). Symptoms lasted from 2-17 days, with a median of 5 days.

The cabins were supplied with water taken from a stream and processed through a small chlorinator and a storage tank that was periodically iodized. A filter had been removed recently from the pipe because it repeatedly became plugged with debris. A severe rainstorm occurred the evening the guests arrived, resulting in increased water turbidity.

Water samples taken at the cabins and the surface stream that supplied the cabins were positive for total coliforms and fecal coliforms. Stool samples from ill patrons were negative for pathogenic bacteria and parasites, except for one sample, from which *Giardia* was isolated. Convalescent-phase sera were submitted to CDC for 13 cases and 26 controls (2 per case), matched for age within 5 years, gender, and city of residence. Controls were selected from health department personnel who had not visited the lodge. No difference in Norwalk titers was found between five cases and five controls.

Under the supervision of state environmentalists, the water system was renovated before the lodge reopened, with particular emphasis on filters, the chlorinator, and the storage tank.

Reported by: PA Bonrud, MS, AL Volmer, TL Dosch, W Chalcraft, D Johnson, B Hoon, M Baker, KA Senger, State Epidemiologist, South Dakota State Dept of Health. CF Martinez, TO Madrid, MPA, RM Gallegos, MS, SP Castle, MPH, CM Powers, JA Knott, RM Gurule, MS Blanch, LJ Nims, MS, PW Gray, PA Gutierrez, MS, M Eidson, DVM, MV Tanuz, HF Hull, MD, State Epidemiologist, New Mexico Health and Environment Dept. Respiratory and Enteroviral Br, Div of Viral Diseases, Center for Infectious Diseases, CDC.

Viral Gastroenteritis - Continued

Editorial Note: The two outbreaks of gastroenteritis described above are representative of those frequently reported to CDC. They demonstrate the need for an improved, specific laboratory approach to identify the agents (many of which are presumed to be viral) responsible for these outbreaks (1,2). Transmission of these viruses is often associated with fecal contamination of water sources used for drinking, swimming, or producing ice (3). Additionally, the contamination of coastal water poses a special problem, since the consumption of seafood is a risk factor for acquiring Norwalk agent infection and other enteric viral agents.

The two best-known enteric viral agents, rotavirus (group A) and Norwalk agent. were first seen in the stools of diarrhea patients by means of electron microscopy in the early 1970s. Both agents have proven to be important causes of gastroenteritis in this country, with rotavirus being the most common agent for diarrhea in young children (4) and Norwalk agent being common in adults (5). In recent years, enteric adenoviruses, non-group A rotavirus, and several 27- to 32-nm enteric viruses, including other Norwalk-like agents, caliciviruses, astroviruses, and other enteric viral pathogens, reportedly have been associated with gastroenteritis (1,6). Recent advances in identifying and diagnosing some of these viruses should make it possible to reduce the number of undiagnosed outbreaks in future investigations. Methods for serologic and antigenic tests are available for some agents, but the examination of stool samples by electron microscopy offers the possibility of identifying agents for which no specific tests are available. The probability of detecting viral particles by electron microscopy is greatest if stool specimens are collected during the early stages of illness, preferably within 12 hours and no later than 48 hours after onset. Some viral particles may be more stable if stool samples are stored at 4 °C. The following guidelines are currently recommended for specimen collection specifically for diagnosing outbreaks of viral gastroenteritis.

- 1. Stool specimens should be collected in bulk volume as soon after the time of disease onset as possible and no later than 48 hours after the onset of symptoms.
- 2. Stool specimens should be refrigerated, not frozen, and shipped to the laboratory on the same day that the specimen is collected.
- 3. Paired serum specimens that are collected within 1 week of the disease onset (acute phase) and 3 to 4 weeks after the onset of symptoms (convalescent phase) from both ill patients and controls are required to establish the causal association between agents seen in the stools and the illness.

References

- Dolin R, Treanor JJ, Madore HP. Novel agents of viral enteritis in humans. J Infect Dis 1987;155:365-76.
- Ciba Foundation. Novel diarrhoea viruses. Chichester, United Kingdom: Wiley, 1987. (Symposium no. 128).
- Centers for Disease Control. Outbreak of viral gastroenteritis—Pennsylvania and Delaware. MMWR 1987;36:709-11.
- Brandt CD, Kim HW, Rodriguez WJ, et al. Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol 1983;18:71-8.
- Kapikian AZ, Chanock RM. Norwalk group of viruses. In: Fields BN, ed. Virology. New York: Raven Press, 1985:1495-517.
- Cubitt WD, Blacklow NR, Herrmann JE, Nowak NA, Nakata S, Chiba S. Antigenic relationships between human caliciviruses and Norwalk virus. J Infect Dis 1987;156:806-14.

Current Trends

Recommendations for Protecting Human Health Against Potential Adverse Effects of Long-Term Exposure to Low Doses of Chemical Warfare Agents

In 1970, Congress gave the Department of Health and Human Services (DHHS) responsibility for reviewing Department of Defense (DOD) plans for transporting and/or disposing of certain chemical agents and making recommendations for the protection of human health and safety (Public Law [Pub. L.] 91-121/441 [50 USC 1512]). DHHS has delegated this authority to CDC. In 1985, Congress passed Pub. L. 99-145 (50 USC 1521), which mandates destruction of the present stockpile of selected chemical agents by September 30, 1994. The specific agents are listed below. In the absence of federal regulatory standards, DOD developed safety and health standards for handling these agents. In reviewing these standards and making its recommendations, CDC sought the assistance of a working group of experts.

The national stockpile of chemical agents includes six chemicals:

Nerve Agents

GA (Tabun or ethyl N,N-dimethylphosphoramidocyanidate)

GB (Sarin or isopropyl methylphosphonofluoridate)

VX (S-[2-diisopropylaminoethyl] O-ethyl methyl phosphonothiolate)

Vesicants/Blister Agents

. H, HD (Sulfur mustard or di-2-chloroethyl sulfide)

T (Bis[2-chloroethylthioethyl] ether)

L (Lewisite or dichloro [2-chloroviny]] arsine)

Like a number of widely used insecticides, the nerve agents GA, GB, and VX are organic compounds containing phosphorus (organophosphorus compounds). They affect nerves, muscles, and glands by inhibiting acetyl cholinesterase, an enzyme required for proper function of these tissues. H and L (an organic compound containing arsenic) are vesicants. They cause chemical burns or blisters of the skin and mucous membranes, such as the conjunctiva of the eyes and the mucosa of airways. The bulk of the national stockpile consists of H, VX, and GB; therefore, CDC, through open meetings, convened a working group of experts to consider adverse effects of acute exposure to these agents.

In 1987, DOD published an environmental impact statement that discussed options for destroying the national chemical stockpile. The preferred alternative was onsite incineration. DOD proposed building an incinerator at each of eight locations and burning the agent for complete chemical breakdown. The recommended control limits are based on air concentrations (Table 1). During public meetings held at each of the eight sites, citizens voiced their concerns about chronic low-level exposure to the agents and the delayed effects that acute exposure might cause. To resolve questions about these concerns, CDC gathered data on these agents and held an open meeting with the working group on September 29-30, 1987, in Atlanta, Georgia. The group discussed the potential health hazards that might result from the destruction of the stockpile, including organophosphate-induced delayed neuropathy, electroencephalographic (EEG) changes, cancer, birth defects, and keratitis. The group studied published and unpublished reports of all potential adverse effects, including carcinogenicity, mutagenicity, and teratogenicity, for the aforementioned agents. In addition,

Exposure - Continued

the U.S. Army Surgeon General's Office summarized a number of studies now under way or recently completed for agents GB, VX, HD, and L.

Nerve degeneration is considered an unlikely outcome either from acute intoxication with any of the nerve agents or from long-term exposure to them. Given the difficulty of demonstrating EEG changes and the absence of clinically significant effects even if the EEG changes are present, members of the working group considered the EEG changes reported after intoxication with GB to be questionable. None of the nerve agents have been shown to be mutagenic or carcinogenic. Results of recently completed studies on GB and initial reports of studies on VX indicate no teratogenic effect.

Available epidemiologic data indicate that H is a human carcinogen. Although the data suggest that H is less potent than such other known human carcinogens as smoking, radon, and chromates, they do not permit an estimate of the carcinogenic potency or the exact degree of the carcinogenic risk with confidence. Very little information is available on the long-term toxicity of agent T, which has much lower volatility than H, with which it is mixed. It is not expected to constitute an airborne hazard unless H is also present at concentrations much higher than permitted. Recommended control limits for agent T are therefore identical to those for H.

Toxicologic information specific to L is sparse. More is known about arsenic-containing compounds in general, but caution must be used in extrapolation. Some evidence suggests that L might be a carcinogen. The recommended control concentration limit, 0.003 mg/m³ (measured as L), in air should be adequate to protect public health. The Occupational Safety and Health Administration (OSHA) has promulgated a standard of 0.5 mg/m³ (measured as arsenic) for organic arsenic concentrations in workplace air. The National Institute for Occupational Safety and Health (NIOSH) has recommended a standard of 0.002 mg/m³ for all forms of arsenic. The proposed L control limits are lower than the existing OSHA occupational standard for

TABLE 1. Recommended control limits for selected chemical agents

Chemical Agent*	Gen Popul (mg/	ation		rkers /m³)
Nerve Agents [†]				
GA, GB	0.000003	(3x10 ⁻⁶)	0.0001	$(1x10^{-4})$
VX	0.000003	(3x10 ⁻⁶)	0.00001	$(1x10^{-5})$
Vesicants [§]				
H, HD, HT ^f	0.0001	(1×10 ⁻⁴)	0.003	$(3x10^{-3})$
L	0.003	(3x10 ⁻³)	0.003	$(3x10^{-3})$
Averaging Time	72 ho	urs	8 h	ours

^{*}Protection against exposure to agents in aerosol and liquid form must be sufficient to prevent direct contact with the skin and eyes.

[†]GA = Tabun or ethyl N,N-dimethylphosphoramidocyanidate; GB = Sarin or isopropyl methylphosphonofluoridate; VX = S-(2-diisopropylaminoethyl) O-ethyl methyl phosphonothiolate.

 $^{^{\}S}H$ or HD = Sulfur mustard or di-2-chloroethyl sulfide; HT = Bis(2-chloroethylthioethyl) ether (T) in a mixture with sulfur mustard; L = Lewisite or dichloro (2-chlorovinyl) arsine.

⁶Data supporting the ability to monitor for H at 0.0001 mg/m³ at all sites should be developed. HT is measured as HD.

Exposure - Continued

organic arsenic by a factor of approximately 500 and are lower than the NIOSH recommended standard by a factor of 2.

Reported by: Special Programs Group, Office of the Director, Center for Environmental Health and Injury Control, Centers for Disease Control.

Editorial Note: CDC, in its continuous oversight of demilitarization activity, routinely examines each of the eight chemical storage sites in the United States and a chemical munitions incineration facility that has been in operation in Utah since 1979. Consideration is given to the population centers in the surrounding communities at depots. Standard operating procedures for agent handling and worker safety are also observed. This experience indicates that the control limits in Table 1 are attainable. Questions related to the nerve agents have been relatively easy to resolve. The information bases are fairly complete, and there appears to be little risk either of adverse health effects from long-term exposure to low doses or of delayed health effects from acute exposure.

(Continued on page 79)

TABLE I. Summary - cases of specified notifiable diseases. United States

	5t	h Week Endi	ng	Cumulative, 5th Week Ending				
Disease	Feb. 6, 1988	Feb. 7, 1987	Median 1983-1987	Feb. 6, 1988	Feb. 7, 1987	Median 1983-1987		
Acquired Immunodeficiency Syndrome (AIDS) Aseptic meningitis Encephalitis: Primary (arthropod-borne	746 66	236 86	156 86	2,629 353	1,601 454	508 454		
& unspec) Post-infectious	12	17 3	17 1	55 5	74 5	75 6		
Gonorrhea: Civilian Military	13,873 274	15,398 252	15,802 407	65,007 1,062	85,593 1,679	81,008 1,819		
Hepatitis: Type A Type B Non A, Non B	571 378 42	435 467 56	448 467 71	2,027 1,397 156	2,076 2,006	2,076 2,040 283		
Unspecified Legionellosis	48 11	62 7	94 11	187 40	283 296 69	365 56		
Leprosy Malaria	4 7	8 17	1 14	8 39	24 59	24 55		
Measles: Total* Indigenous	22 20	23 19	23 19	103 99	112 91	112 88		
Imported Meningococcal infections Mumps	2 58 121	4 75 468	4 71 61	4 279	21 352	21 273 301		
Pertussis Rubella (German measles)	33	39	24	325 95 10	1,274 174 21	129 23		
Syphilis (Primary & Secondary): Civilian Military	766 4	670	616 3	3,172 14	3,185 6	2,649 17		
Toxic Shock syndrome Tuberculosis	6 310	9 361	9 362	21 1,241	27 1,55 <u>2</u>	35 1,552		
Tularemia Typhoid Fever Typhus fever, tick-borne (RMSF)	8	2 3 1	2 3 1	12 26 6	9 19 5	9 24 6		
Rabies, animal	35	55	77	227	301	335		

TABLE II. Notifiable diseases of low frequency, United States

^{*}Two of the 22 reported cases for this week were imported from a foreign country or can be directly traceable to a known internationally imported case within two generations.

TABLE III. Cases of specified notifiable diseases, United States, weeks ending February 6, 1988 and February 7, 1987 (5th Week)

		Aseptic	Encer	halitis			Hepatitis (Viral), by type				I	
Reporting Area	AIDS	Menin- gitis	Primary	Post-in- fectious	(Civ	orrhea ilian)	Α	В	NA,NB	Unspeci- fied	Legionel- losis	Leprosy
	Cum. 1988	Cum. 1988	Cum. 1988	Cum. 1988	Cum. 1988	Cum. 1987	Cum. 1988	Cum. 1988	Cum. 1988	Cum. 1988	Cum. 1988	Cum. 1988
UNITED STATES	2,629	353	55	5	65,007	85,593	2,027	1,397	156	187	40	8
NEW ENGLAND	98	17	2	-	1,952	3,027	64	98	7	20	1	3
Maine N.H.	6 4	2 4	1	-	42 38	101 47	1 4	3 2	2	-	-	-
Vt.	-	1	-	-	17	18	-	2	-	-	-	-
Mass. R.I.	56 7	5 4	1	-	630 110	1,132 238	45 12	84 6	4 1	20	1 -	3
Conn.	25	1	-	-	1,115	1,491	2	1	-	-	-	-
MID. ATLANTIC	756	45	5		7,383	14,229	101	128	11	12	10	1
Upstate N.Y.	96	27	4	-	1,016	1,403	63	38	5	-	10	:
N.Y. City N.J.	336 215	3 15	1	-	4,250 1,406	8,936 1,038	18 20	52 38	6	9 3		1
Pa.	109	-	-	-	711	2,852	-	-	-		-	-
E.N. CENTRAL	260	50	6	-	10,738	11,452	325	159	9	11	9	-
Ohio Ind.	65 1	21 5	3 2	-	2,561 765	2,615 871	256 5	54 3	2	3	-	-
III.	116	-	-		3,234	3,250	6	5	-	1	-	-
Mich. Wis.	63	23	1	-	3,687 491	3,776 940	54 4	91 6	7	7	8	-
	15	1	-								1	-
W.N. CENTRAL Minn.	77 20	18 6	4 1	1	2,635 363	3,449 583	137 5	52 7	7	1	4	-
lowa	4	3	3	-	232	336	5	10	2	-	2	-
Mo. N. Dak.	27	2	-	-	1,501 16	1,741 30	56 1	27	2	-	-	-
S. Dak.	3	4		1	51	84		-	-	-		
Nebr.	8	-		-	157	189	11	5	1	-	2	-
Kans.	15	3	•	-	315	486	59	3	2	-	•	-
S. ATLANTIC Del.	313 3	67 3	5	1	17,557 273	22,567 301	82	258 9	12	39 1	7 1	-
Md.	58	8			1,564	1,883	11	33	1		i	-
D.C.	31	2	-	-	970	1,378	1	1	1	-	-	-
Va. W. Va.	2 3	8 3	4	-	1,495 180	1,910 133	10	19 6	2	30 2	-	-
N.C.	38	8	1	-	2,676	3,466	17	60	5	3	2	-
S.C. Ga.	18 76	4	-	•	1,386 3,154	2,370 3,648	2 9	75 15	2	•	1	-
Fla.	76 84	31		1	5,859	7,478	32	40	1	3	2	-
E.S. CENTRAL	86	26	5	1	5,443	5,791	56	76	13	2	3	_
Ky.	4	11	2	-	458	607	48	14	4	1	1	-
Tenn. Ala.	50 20	3 10	2 1	1	1,525 2,197	1,911 1,944	6	30 31	6 3	1	1 1	-
Miss.	12	2		-	1,263	1,329	2	1	-			
W.S. CENTRAL	269	12	_	-	8,641	9,910	99	69	4	15	1	_
Ark.	6	1	-	-	636	1,039	13	6		1	-	-
La. Okla.	38 12	1 3		-	2,599 604	1,348 1,007	2 21	21 16	1 1	2	1	-
Tex.	213	7	-	-	4,802	6,516	63	26	2	12	-	-
MOUNTAIN	128	13	8	1	1,422	2,175	348	160	20	24	4	-
Mont. Idaho	3	-	-	-	35 33	47 73	5 12	7 11	1	2	-	-
Wyo.	-		-		33 16	20	- 12	- ''	-	-		-
Colo.	53	5	2	-	371	452	15	22	2	7	2	-
N. Mex. Ariz.	7 45	1	2	-	159 484	233 763	64 189	14 76	1 9	9	-	•
Utah	13	6	3	1	66	94	47	10	5	5	2	-
Nev.	7	1	1	-	258	493	16	20	2	1	•	-
PACIFIC	642	105	20	1	9,236	12,993	815	397	73	63	1	4
Wash. Oreg.	1 36	-	-	-	575 323	916 470	75 188	25 70	6 10	1 2	:	-
Calif.	592	86	19	1	8,097	11,227	515	293	56	59	1	4
Alaska Hawaii	6	4	-	-	124	259 121	37	9	1	1	-	-
Hawaii	7	15	1	-	117	121	-	-	-	-	-	-
Guam P.R.	12	2	1	-	13 154	26 232	1	1 27	2	1 6	-	-
V.I.	- 12	-	-	-	42	24		-	-	-	-	-
Amer. Samoa	-	-	-	-	-	42	-	-	-	-	-	-
C.N.M.I.	-	-	-	-	6	12	-	1	-	-	-	-

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending February 6, 1988 and February 7, 1987 (5th Week)

	Measles (Rubeola)						Menin-								
Reporting Area	Malaria	Indig	enous	Impo		Total	gococcal Infections	Mu	mps		Pertussi	is		Rubella	1
	Cum. 1988	1988	Cum. 1988	1988	Cum. 1988	Cum. 1987	Cum. 1988	1988	Cum. 1988	1988	Cum. 1988	Cum. 1987	1988 Cum. 1988	Cum. 1988	Cum. 1987
UNITED STATES	39	20	99	2	4	112	279	121	325	33	95	174	3	10	21
NEW ENGLAND Maine	4	-	1	-	-	5	29	-	3	9	13	3		-	-
N.H. Vt.	:	-	-	-		-	5	-	2	9	11	1	-	-	-
Mass. R.I.	3	-	1	-	-	5	15	-	1		-	1	-	-	-
Conn.	1	-	-		-	-	5 4	-	-	:	2	1		-	-
MID. ATLANTIC Upstate N.Y.	5 3	7	23	•	-	32 2	28	2	14	1	4	22		-	-
N.Y. City	2	4	4	-	-	18	16 3		2	1	2	16	-	-	-
N.J. Pa.	-	3	19	-	-	1 11	9	2	5 7		2	1 5	-	-	-
E.N. CENTRAL Ohio	2	-	-		-	24	33	22	79	3	6	33	-	-	2
Ind.	-		-	-		-	16 1	15	15 6	2	2	15	-	-	-
III. Mich.	2	-	-	-		2 22	1 12	7	5 44	1	4	5	-	-	1
Wis.	-	-	-	•	-	-	3	-	9	-	-	13	-	-	-
W.N. CENTRAL Minn.	1	-	-	-		-	10 1	14	37		10	17 2			
lowa Mo.	-	:	-	-			6	5 3	13 10	-	3	2	-	-	-
N. Dak. S. Dak.	-	-	-	:	-	-	-	-	-		4	1			-
Nebr. Kans.	-	-	-		-	-	:	-	1		2	1	-	-	-
S. ATLANTIC	6	-	-	•	2	-	3 30	6 3	13		1	4	-	-	-
Del. Md.	1	-	-	-	•		-	-	13	3	13 1	36	-	-	-
D.C.	-	-	-	-	1 -	-	3	1	1	-	-		-	-	-
Va. W. Va.	1 -	-	-	-		-	4	-	3	-	1	16 3	:	-	-
N.C. S.C.	3	-	-	-	1	-	4 5	1	3 1	3	8	15	-	-	-
Ga. Fla.	1	-	-	-	-	-	4 10	-	2	-	3	2	-	•	-
E.S. CENTRAL	1	-	-	_	_		31	1 31	3 67	1	3	3		-	2
Ky. Tenn.	-	:	-	-	-	-	6	6	7	-	-	1		-	2
Ala. Miss.	1	-	-	-	-	-	16 9	24	58 1	1	3	-		-	-
W.S. CENTRAL	3		-	•	-	-	-	N	N	-	-	2	-	-	-
Ark.	-	-	-	-	-	-	11 3	8 1	24 1	-		5	-	-	-
La. Okla.	3	-	-	-	-	-	-	2	7 7	-		- 5	-	-	-
Tex. MOUNTAIN	1	-	٠	-	-	-	8	5	9	-	-	-	-	-	1
Mont.	-	8	35	-	-	2	12	7	19		11	9	-	-	-
ldaho Wyo.	-	-	-	-	-	-	1	-	1	-	7 1	2	-	-	-
Colo. N. Mex.	-	8	35	-	-	1	4 4	- Ni	2	-		6	-	-	-
Ariz. Utah	-	-	-	-	-	i	2	N 5	N 13	-	1	-	-	-	1
Nev.	1	-	-	-	-	-	1 -	2	1 2	-	2	-	-	-	:
PACIFIC Wash.	16 1	5	40	2	2	49	95	34	69	16	35	46	3	10	16
Oreg.	2	-	-	:.	:	1	5 9	N	1 N	1 -	3 2	5 8	-	-	1 14
Calif. Alaska	12 1	5	40	1†	1	48	77 1	33 1	65 3	14	21	30 1	2	9	-
Hawaii C	-	-	-	1†	1		3	-	-	1	9	2	1	1	1
Guam P.R.	1	-		-	-	1	2	-	2	-	-	4	-	-	-
V.I. Amer. Samoa	-		-	-	-	-	-	1	6	-	-	-	-		-
C.N.M.I.	-	-	-	-	-	-		-	- :	-	-	-	-	-	-

^{*}For measles only, imported cases includes both out-of-state and international importations.

N: Not notifiable U: Unavailable †International *Out-of-state

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending February 7, 1988 and February 6, 1987 (5th Week)

Reporting Area	Syphilis (Primary &	(Civilian) Secondary)	Toxic- shock Syndrome	Tuber	culosis	Tula- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Rabies, Animal
	Cum. 1988	Cum. 1987	Cum. 1988	Cum. 1988	Cum. 1987	Cum. 1988	Cum. 1988	Cum. 1988	Cum. 1988
UNITED STATES	3,172	3,185	21	1,241	1,552	12	26	6	227
NEW ENGLAND	91	45	4	19	27	-	4	-	2
Maine N.H.	2 1		1 2	2	1 1	-	-	-	2
Vt.	-	-	•	-	1	-	-	-	-
Mass. R.I.	34 3	30	1	8 1	6	-	3	-	-
Conn.	51	15	-	8	18	-	1	-	-
MID. ATLANTIC	595	391	1	240	304	-	2	-	19
Upstate N.Y. N.Y. City	41 469	6 257	1	51 76	58 139	-	1	-	-
N.J.	75	57	-	60	60	-	-	-	
Pa.	10	71	-	53	47	-	-	-	19
E.N. CENTRAL Ohio	87 5	104 7	1	197 38	217 34	1 -	-	-	6
Ind.	11	6	-	13	3	-	-	-	-
III. Mich.	46	70	;	72 65	101 74	1	-	-	2
Wis.	24 1	11 10	1 -	65 9	5		-	-	4
W.N. CENTRAL	13	15	4	36	45	5	-	-	45
Minn. Iowa	1	4	•	9 3	6 5	-	-	-	18
Mo.	2 4	2 9	1 2	16	25	4	-	-	11 1
N. Dak.	-	-	-	-	1	-	•	-	4
S. Dak. Nebr.	1 2	-	1	8	2 3	1	-	-	6 1
Kans.	3	-	•	-	3	-	-	-	4
S. ATLANTIC	1,128	1,086	3	271	303	1	1	6	56
Del. Md.	17 56	10 50	-	3 31	1 28	1 -	-	•	21
D.C.	49	22	-	10	12	-	-	-	-
Va. W. Va.	33 1	32	-	41 7	34 12	-	-	-	14 4
N.C.	68	60	2	9	36	-	-	6	-
S.C. Ga.	35	72	•	43 14	44 19	-	1	-	1 16
Fla.	186 683	175 665	1	113	117	-	-	-	-
E.S. CENTRAL	185	208	4	114	181	3	-	-	13
Ky. Tenn.	3	-	2	40 18	24 45	3	-	-	8
Ala.	51 73	75 54	1 1	47	59	-	-		5
Miss.	58	79	-	9	53	•	-	-	-
W.S. CENTRAL Ark.	358	439	-	78	109	-	-	-	35
La	2 50	18 49	-	5 19	7 25	-	-	-	9
Okla.	16	18	-	17	13	-	-	•	4
Tex.	290	354	-	37	64	-		-	22
MOUNTAIN Mont.	70	74	1	16	31	2	2 1	-	23 19
Idaho	2	3 1	1	-	2	-	-	-	-
Wyo. Colo.		-	-	-	2	2	1	-	2
N. Mex.	13 7	8 7	-	2 6	6	-		-	1
Ariz. Utah	12	35	-	6	18	-	-	-	1
Nev.	4 32	20	-	2	3	-	-		-
PACIFIC	645	823	3	270	335	_	17	-	28
Wash	045	823 14	-	14	10	-	2	-	-
Oreg. Calif.	14	13	3	12 224	13 283	-	1 12	-	28
Alaska	627	795	3 -	3	7	-	-	-	•
Hawaii	4	1	-	17	22	-	2	-	-
Guam P.R.	-	-	-		2	-	-	-	-
V.I.	69 1	88 2	-	11	15 1	-	-	-	6
Amer. Samoa	-	2	-	-	13	-	-	-	-
C.N.M.I.	-	-	-	-	-	-	-	-	-

TABLE IV. Deaths in 121 U.S. cities,* week ending February 6, 1988 (5th Week)

repruary 6, 1988 (5th week)															
		All Cau	uses, B	y Age	Years)		P&I**			All Cau	ıses, B	y Age	(Years)		P&I**
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-84	25-44	1-24	<1	Total
NEW ENGLAND	632	443	111	40	15	23	56	S. ATLANTIC	1,555	948	356	138	49	63	69
Boston, Mass. Bridgeport, Conn.	196 51	125 42	36 7	19 1	8	8 1	19 3	Atlanta, Ga.	214 298	122	42	20	7	23	5 15
Cambridge, Mass.	18	13	4	i	-	-	6	Baltimore, Md. Charlotte, N.C.	298 83	172 47	83 24	23 6	10 4	10 2	5
Fall River, Mass.	35	26	6	1	:	2	1	Jacksonville, Fla.	114	70	30	10	2	2	6
Hartford, Conn. Lowell, Mass.	45 23	31 15	7 5	5 3	1	1	1 2	Miami, Fla.	239	138	55	28	10	8	1
Lynn, Mass.	31	22	6	3		-	2	Norfolk, Va. Richmond, Va.	57 86	37 56	13 20	2 6	1	4 3	1 11
New Bedford, Mass.	27	22	4	1	-	-	3	Savannah, Ga.	59	39	13	5	2		7
New Haven, Conn. Providence, R.I.	27 33	14 24	3	2	2	8 1	2 1	St. Petersburg, Fla.	104	87	7	2	5	3	7
Somerville, Mass.	7	- 5	2	-	-			Tampa, Fla. Washington, D.C.	71 201	47 113	13 50	5 28	2 5	3 5	5 5
Springfield, Mass.	47	30	11	2	4	-	4	Wilmington, Del.	29	20	6	3	-	-	1
Waterbury, Conn. Worcester, Mass.	34 58	29 45	5 11	-	-	2	7 5	E.S. CENTRAL	935	631	192	62	23	27	64
·								Birmingham, Ala.	113	62	28	13	3	7	1
MID. ATLANTIC : Albany, N.Y.	2,916 53	1,970 36	574 11	231 2	77 3	64 1	149 1	Chattanooga, Tenn.	77	60	15	1	1	-	6
Allentown, Pa.	19	15	3	ī		-		Knoxville, Tenn. Louisville, Kv.	126 132	92 89	16 30	14 7	4 3	3	9 14
Buffalo, N.Y.§	108	74	23	8	1	2	7	Memphis, Tenn.	255	176	47	15	10	3 7	22
Camden, N.J. Elizabeth, N.J.	28 26	11 21	13 5	3	-	1	•	Mobile, Ala.	72	46	16	4	1	5	4
Erie, Pa.†	45	31	10	1	1	2	1 7	Montgomery, Ala. Nashville, Tenn.	43	34	8	-	1	5	3 5
Jersey City, N.J.	54	42	8	2	1	1	2		117	72	32	8			
N.Y. City, N.Y. Newark, N.J.	1,525 41	990 17	295 11	158	56	26	73	W.S. CENTRAL Austin, Tex.	1,421 74	890 57	318 9	120 6	51 1	39 1	66 7
Paterson, N.J.	27	15	7	10 1	1 2	2	5 3	Baton Rouge, La.	55	33	17	2	i	ż	2
Philadelphia, Pa.	486	335	109	24	6	12	18	Corpus Christi, Tex.	32	29	2	-	1	-	1
Pittsburgh, Pa.†	78 41	47	18	3	2	8	-	Dallas, Tex. El Paso, Tex.	210 57	118 32	54 18	18 4	10 1	10 2	3 3
Reading, Pa. Rochester, N.Y.	115	36 86	5 21	6	1	1	1 14	Fort Worth, Tex	110	76	19	7	6	2	5
Schenectady, N.Y.	29	24	2	2	i	-	1	Houston, Tex.§	308	176	74	34	13	11	7
Scranton, Pa.†	40	29	9	2	-	-	-	Little Rock, Ark.	108	63	22	13	2	5	6
Syracuse, N.Y. Trenton, N.J.	89 49	72 35	12 7	3 4	1	2	8 3	New Orleans, La. San Antonio, Tex.	108 215	65 137	25 55	15 12	3 8	3	23
Utica, N.Y.	20	18	í	-		1	3	Shreveport, La.	23	18	4	1	-	-	1
Yonkers, N.Y.	43	36	4	1	1	1	2	Tulsa, Okla.	121	86	19	8	5	3	8
	2,377	1,596	507	144	45	79	120	MOUNTAIN	649	447	135	37	16	14	45
Akron, Ohio	80 43	57	16	5	1	1	3	Albuquerque, N. Mex Colo. Springs, Colo.	k. 81 43	63 31	9 7	5 2	3 1	1 2	3 6
Canton, Ohio Chicago, III.§	564	36 362	6 125	1 45	10	22	12 16	Denver, Colo.	66	45	13	5	i	2	3
Cincinnati, Ohio	134	81	39	7	3	4	10	Las Vegas, Nev.	108	76	24	4	3	1	13
Cleveland, Ohio	156	91	48	11	3	3	3	Ogden, Utah	20	13	3	2	1	1 5	2 5
Columbus, Ohio Dayton, Ohio	129 115	84 83	30 22	6 6	3 1	6 3	2 4	Phoenix, Ariz. Pueblo, Colo.	137 30	90 21	29 5	10 4	3	-	1
Detroit, Mich.	223	133	54	16	11	9	6	Salt Lake City, Utah	40	21	14	3	1	1	-
Evansville, Ind.	46	34	10	-	-	9 2 3	4	Tucson, Ariz.	124	87	31	2	3	1	12
Fort Wayne, Ind. Gary, Ind.	85 21	56 10	18 7	8 1	-	3	6 1	PACIFIC	2,295	1,581	395	171	66	67	180
Grand Rapids, Mich.	58	39	12	4	1	3	6	Berkeley, Calif. Fresno, Calif.	17 123	15	2 22	7	3	6	2 19
Indianapolis, Ind.	173	115	37	8	5	8	4	Glendale, Calif.	49	84 37	6	4	1	-	2
Madison, Wis. Milwaukee, Wis.	45 148	30 119	8 23	5 5	1	1	4	Honolulu, Hawaii	81	56	18	3	3	1	11
Peoria, III.	60	42	10	3	2	1	10 9	Long Beach, Calif. Los Angeles Calif.	53	41	6	4	1	1	7 30
Rockford, III.	47	37	7	2	ī		7	Oakland, Calif.	646 80	431 63	115 11	53 3	23 1	11 2	1
South Bend, Ind.	16	13	3	-	-	-	. 1	Pasadena, Calif.	56	40	10	1	2	3	10
Toledo, Ohio Youngstown, Ohio	133 101	97 77	21 11	6 5	3	6 2	11	Portland, Oreg.	149	108	24	6	3	8	9
W.N. CENTRAL	965	684	181	49	10			Sacramento, Čalif. San Diego, Calif.	184 198	133 131	23 37	15 19	5	8 5	16 20
Des Moines, Iowa	965 50	38	10	49	19 1	32	71 2	San Francisco, Calif.	185	112	38	26	2	7	10
Duluth, Minn.	20	15	3	-	i	1	2	San Jose, Calif.	192	132	31	14	9	6	25
Kansas City, Kans.	40	32	6	1	-	1	:	Seattle, Wash. Spokane, Wash.	165 54	115 40	31 11	12 1	2	5 2 2	4
Kansas City, Mo. Lincoln, Nebr.	113 43	66 33	27 7	11 2	5	4	4 6	Tacoma, Wash.	63	40	10	3	5	2	10
Minneapolis, Minn.	322	237	49	17	7	12	35	1	13,745 ^{††}			992	361	408	820
Omaha, Nebr.	65	51	10	3	-	1	8	. O IAL	.5,,-5	3,130	2,703	332	301	400	020
St. Louis, Mo.	151	98 58	38	4	3	8	5								
St. Paul, Minn. Wichita, Kans.	83 78	56	16 15	6 4	1	2	2 7								
				•	•	-	•								

^{*}Mortality data in this table are voluntarily reported from 121 cities in the United states, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

Included.
**Pneumonia and influenza.

**Pneumonia and influenza.

**Because of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week.

Complete counts will be available in 4 to 6 weeks.

††Total includes unknown ages.

\$Data not available. Figures are estimates based on average of past 4 weeks.

Exposure - Continued

Exposure to or contact with H by any route—respiratory, skin, or oral—should be limited to the extent practicable. This can be accomplished by use of appropriate engineering controls, personal protective equipment, and work practices. Concentrations in the workplace and surrounding air should be measured and verified by instruments that can reliably detect concentrations at or below the control limits. At this time, the most sensitive monitors can reliably measure 0.003 mg/m³ of H and L in the workplace air. Because of dispersion and dilution, this level would be adequate protection for the general population.

The members of the working group also considered DOD's proposal for agent stack emission levels during incineration. These limits should be 1) attainable by a well-designed, constructed, and operated incineration facility, 2) capable of offering an early indication of disturbed operating conditions, and 3) able to be accurately measured in a timely manner. The allowable stack concentrations proposed by DOD meet these criteria and appear to restrict emissions to concentrations well below those that would endanger health. They must be evaluated by air dispersion modeling of credible worst-case events and conditions specific to each site to ensure that they will not result in emissions exceeding the permissible level for the general population and the workplace.

On the basis of the evidence reviewed, members of the working group concluded that human health will be adequately protected from exposure to the chemical agents at the recommended concentrations in this report. Even long-term exposure to these concentrations would not create adverse health effects. The relatively short duration of the disposal program provides an additional margin of safety.

Epidemiologic Notes and Reports

La Crosse Encephalitis in West Virginia

Between July 6 and September 1, 1987, in central West Virginia, 19 cases of La Crosse encephalitis were serologically confirmed (Figure 1). After a cluster of meningo-encephalitis cases was reported from a referral pediatric service in Charleston, active hospital-based surveillance was undertaken in 15 counties in central and southern West Virginia, where La Crosse encephalitis had previously occurred. Cases were identified in five of these counties.

Eleven (58%) of the 19 patients were diagnosed as having viral encephalitis. Four (21%) had symptoms of meningitis alone, and four (21%) had meningo-encephalitis. The patients ranged in age from 1 to 14 years (mean = 7 years). Fifteen (79%) patients were male; the male-to-female ratio was 3.8:1. Eighteen (95%) children were hospitalized, and one child was treated as an outpatient. One patient, a 9-year-old boy with cerebral edema, died despite intensive supportive care.

All patients lived in rural areas of central West Virginia, a region with thick hardwood forests conducive to mosquito breeding. Attack rates varied by the patients' sex and place of residence (Table 1). Males were at much greater risk of becoming ill than females. The attack rate among children under 15 years of age in Nicholas County was over four times the rate in any other county. A case-control study is under way to test hypotheses regarding possible behavioral and environmental risk factors.

Encephalitis - Continued

For six (32%) of the patients, diagnosis was based on compatible clinical findings and a single immunofluorescent antibody (IFA) titer >128 during the convalescent stage of illness. For the other 13 (68%), a fourfold rise in antibody titer was demonstrated between the acute and convalescent stages of illness.

In the past, few cases of La Crosse encephalitis have been reported in West Virginia. Of 223 cases of encephalitis reported to the West Virginia Department of Health from 1980 through 1986, only eight (4%)—six in 1984 and two in 1985—were attributed to a California serogroup virus. Much of the increase in reported incidence in 1987 may be the result of intensive case-finding efforts. A change in the state laboratory's serologic procedure for La Crosse virus diagnosis may also have contributed to the increase in the number of identified cases. Previously, serologic diagnoses were made by measuring complement-fixing antibodies. The more sensitive IFA was adopted in 1987.

FIGURE 1. Reported cases of LaCrosse encephalitis, by week of onset — West Virginia, 1987




TABLE 1. Attack rates of La Crosse encephalitis, by sex and county of residence — West Virginia, July 6-September 1, 1987

County	M	lales	Fei	males	T	Total	
	No.	Rate*	No.	Rate*	No.	Rate*	
Nicholas	5	129	3	84	8	107	
Greenbrier	2	45	_	0	2	23	
Fayette	3	41	_	0	3	21	
Kanawha	4	16	1	4	5	10	
Logan	1	14	_	0	1	7	
Total	15	31	4	9	19	20	

^{*}Attack rate = number of patients <15 years of age per 100,000 population of the same age.

Encephalitis - Continued

Reported by: AA Kindle, JE McJunkin, MD, JR Meek, MD, Charleston Area Medical Center; MM Tomsho, MD, Summersville; DL Holbrook, DL Smith, MD, Nicholas County Health Dept; BA Crowder, DM Rosenberg, MD, Kanawha County Health Dept; JA Burke, DC Newell, DO, Fayette County Health Dept; SL Sebert, MD, Greenbrier County Health Dept; JH Wright, DO, Logan County Health Dept; JW Brough, DrPH, DM Cupit, MS, LE Haddy, MS, RC Baron, MD, Acting State Epidemiologist, West Virginia Dept of Health. Div of Field Svcs, Epidemiology Program Office; Div of Vector-Borne Viral Diseases, Center for Infectious Diseases, CDC.

Editorial Note: La Crosse virus, a bunyavirus in the California serogroup, and its mosquito vector, *Aedes triseriatus*, are widely distributed in the central and eastern United States (1,2). Central nervous system (CNS) infections from La Crosse virus have been recognized chiefly in the upper Midwest. However, reports of sporadic cases from other states suggest that the disease may be endemic in a broader geographic distribution (3,4). The focus of cases in West Virginia in 1987 illustrates the high levels of endemic transmission that may remain undetected unless specific diagnoses are sought.

CNS infections from La Crosse virus occur nearly exclusively among children. Of the 929 cases reported to CDC from 1971-1983, 833 (89.7%) involved children under 15 years of age. Boys are affected more often than girls, presumably because they spend more time outdoors where they are exposed to the vector. Boys accounted for 66.3% of the 833 reported cases involving children. Although the proportion of reported cases involving males in West Virginia in 1987 was higher than the proportion reported elsewhere, it was not significantly greater than expected (p>0.17, binomial distribution).

The incidence of La Crosse encephalitis in the five-county area of central West Virginia (20/100,000 children <15 years of age, 4.7/100,000 total population) was similar to rates reported from other locations where the disease is endemic. In 1978, active, hospital-based surveillance in 20 Wisconsin and Minnesota counties showed an incidence of 31.6/100,000 children under 15 years of age and 6.3/100,000 total population (5).

La Crosse encephalitis is infrequently recognized as a cause of childhood morbidity from CNS infection. Incidence rates for La Crosse encephalitis in endemic areas are similar to rates for *Haemophilus influenzae* meningitis, which range from 35 to 40/100,000 for children under 5 years of age and from 2.2 to 7.7/100,000 for the total population (6). The fatality rate for La Crosse encephalitis is <1%; however, during acute illness, convulsions occur in 50% of cases, and focal weakness, paralysis, or other localized signs occur in 25% (3). Residual convulsive disorders may persist in 10% of cases, and some recovered patients have impaired cognitive performance (3).

Public health measures to control La Crosse encephalitis have focused on eliminating breeding sites for *Ae. triseriatus*, but the importance of tree holes and breeding sites such as tires and other discarded containers in the spread of La Crosse encephalitis has not been well defined. The current case-control study addresses this issue; results of the study will help public health officials planning mosquito control programs to target breeding sites that pose the greatest risk.

References

- Calisher CH. Taxonomy, classification, and geographic distribution of California serogroup bunyaviruses. Prog Clin Biol Res 1983;123:1-16.
- Craig GB Jr. Biology of Aedes triseriatus: some factors affecting control. Prog Clin Biol Res 1983:123:329-41.
- Tsai TF, Monath TP. Viral diseases in North America transmitted by arthropods or from vertebrate reservoirs. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. Vol II. 2nd ed. Philadelphia: WB Saunders, 1987;1417-56.

Encephalitis - Continued

- 4. Kappus KD, Monath TP, Kaminski RM, Calisher CH. Reported encephalitis associated with California serogroup virus infections in the United States, 1963-1981. Prog Clin Biol Res 1983:123:31-41.
- Hurwitz ES, Schell W, Nelson D, Washburn J, LaVenture M. Surveillance for California encephalitis group virus illness in Wisconsin and Minnesota, 1978. Am J Trop Med Hyg 1983;32:595-601.
- Fraser DW, Geil CC, Feldman RA. Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol 1974;100:29-34.

Epidemiologic Notes and Reports

Influenza Update - United States

The following are indicators of influenza activity in the United States for the weeks ending January 16, 23, 30, and February 6. Numbers and percentages in this table are provisional and may change as additional reports are received for the given weeks.

Report Wook Ending

		port we	ek Endir	1g
	Jan	Jan	Jan	Feb
	16	23	30	6
	1988	1988	1988	1988
Influenza-associated morbidity levels reported by state and territorial epidemiologists				
Number of states reporting sporadic activity*	25	29	31	23
Number of states reporting regional activity [†]	5	10	11	17
Number of states reporting widespread activity ⁵	2	2	4	6
Reports from sentinel physicians [¶]	_	-	•	
Patients seen with influenza-like illness, expressed as percent of total patient visits	5%	4%	6%	6%
Sentinel physicians reporting outbreaks, expressed as percent of total number of reports received for week	21%	18%	19%	36%
Isolates reported by WHO Collaborating Laboratories and other laboratories	21/0	1076	1376	3070
Cumulative number of states reporting isolates of influenza A(H3N2)**	16	23	26	32
Cumulative number of states reporting isolates of influenza B ^{††}	6	6	6	9

^{*}Sporadically occurring cases, no known outbreaks.

††States reporting isolates of influenza B to date: Arizona, Hawaii, Montana, Nevada, New York,


Ohio, Tennessee, Washington, and Wisconsin.

[†]Outbreaks in counties whose total population comprises less than 50% of total state population.

⁵Outbreaks in counties whose total population comprises 50% or more of total state population.
¹Members of the American Academy of Family Physicians who submit weekly influenza surveillance reports based on their patient population.

^{**}States reporting isolates of influenza A(H3N2) to date: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Iowa, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Montana, New Mexico, North Dakota, New York, Ohio, Oklahoma, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Washington, West Virginia, Wisconsin, and Wyoming.

FIGURE I. Reported measles cases — United States, Weeks 1-4, 1988



The Morbidity and Mortality Weekly Report is prepared by the Centers for Disease Control, Atlanta, Georgia, and available on a paid subscription basis from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402, (202) 783-3238.

The data in this report are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday. The editor welcomes accounts of interesting cases, outbreaks, environmental hazards, or other public health problems of current interest to health officials. Such reports and any other matters pertaining to editorial or other textual considerations should be addressed to: Editor, Morbidity and Mortality Weekly Report, Centers for Disease Control, Atlanta, Georgia 30333.

Director, Centers for Disease Control James O. Mason, M.D., Dr.P.H. Director, Epidemiology Program Office Carl W. Tyler, Jr., M.D. Editor Michael B. Gregg, M.D. Managing Editor Gwendolyn A. Ingraham

☆U.S. Government Printing Office: 1988-530-111/60059 Region IV

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service Centers for Disease Control Atlanta, GA 30333

Official Business
Penalty for Private Use \$300

FIRST-CLASS MAIL POSTAGE & FEES PAID PHS/CDC Permit No. G-284

Z4 *HCRU9FISD22 8721 DANIEL B FISHBEIN, MD CID, VRL 7-B44 G13 X